Thursday, Jan 4, 1996
South San Francisco, Calif. -- January 4, 1996 --Genentech, Inc. (NYSE: GNE) announced today the promotions of John P. McLaughlin and William D. Young as Executive Vice Presidents. Genentech's Board of Directors unanimously approved the promotions, which were recommended at the company's most recent Board meeting by President and CEO Arthur D. Levinson.
The appointments recognize the tremendous contribution both executives have made to the company, but more important, the appointments acknowledge the roles John McLaughlin and Bill Young play in assisting me in the overall operation of the company, said Levinson. They embody the values, the drive, and the capability that will help assure Genentech's future success.
Until this promotion, John McLaughlin served as Senior Vice President, General Counsel and Secretary. McLaughlin joined Genentech in 1987 as Vice President of Government Affairs. He opened the Washington, D.C. office responsible for managing and expanding the company's relationships both on Capitol Hill and with various regulatory agencies. In February, 1989, McLaughlin was named Vice President, General Counsel and Secretary, with responsibility for the company's Legal and Patent departments.
In June, 1993, he was named Senior Vice President with added responsibility for the Business Development and Corporate Communications functions. McLaughlin obtained his B.A. from the University of Notre Dame in 1973 and his J.D. from the Catholic University of America in 1976.
Most recently Senior Vice President, William Young joined Genentech in 1980 as Director of Manufacturing and Process Sciences. In 1983 he became Vice President of Manufacturing and Process Sciences, and in December, 1988, was promoted to Senior Vice President. He is responsible for all of Genentech's Manufacturing, Process Development, Quality, Regulatory, and Engineering functions. Young has coordinated the design and construction of Genentech's state-of-the-art biotechnology manufacturing facilities, and was instrumental in identifying Genentech's new manufacturing site in Vacaville, Calif., currently under construction. Young received his B.A in Chemical Engineering from Purdue University in 1966, and his MBA from Indiana University in 1971. He was elected to the National Academy of Engineering in 1983. He is a Director of GenVec, Inc., a gene therapy company, and Energy Biosystems, an industrial biotechnology company.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs. Ten of the currently marketed biotechnology products stem from Genentech research, five of which Genentech markets directly.
Genentech is headquartered in South San Francisco, California, and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.
# # #